A new piperidinol derivative targeting mycolic acid transport in Mycobacterium abscessus

Molecular Microbiology

Volumn 101, Issue 3, 2016, Pages 515-529

  Dupont, Christian ^a,b   Viljoen, Albertus ^a   Dubar, Faustine ^c   Blaise, Mickaël ^a   Bernut, Audrey ^a   Pawlik, Alexandre ^d   Bouchier, Christiane ^d   Brosch, Roland ^d   Guérardel, Yann ^c   Lelièvre, Joël ^e   Ballell, Lluis ^e   Herrmann, Jean Louis ^b   Biot, Christophe ^c   Kremer, Laurent ^a,f  

^a UNIV MONTPELLIER   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c UNIV LILLE   (France)

^d INSTITUT PASTEUR   (France)

^e GLAXOSMITHKLINE   (Spain)

^f University of Montpellier I and II   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 CHLORO 3 (TRIFLUOROMETHYL)PHENYL] 1 (2 METHYLBENZYL)PIPERIDIN 4 OL; AMIKACIN; ARABINOGALACTAN; CEFOXITIN; CLARITHROMYCIN; IMIPENEM; MYCOLIC ACID; PIPERIDINE DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL GENOME; BACTERIAL LOAD; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; EMBRYO; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; MAB 4508 GENE; MACROPHAGE; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; ZEBRA FISH;

EID: 84978999475     PISSN: 0950382X     EISSN: 13652958     Source Type: Journal    
DOI: 10.1111/mmi.13406     Document Type: Article

References (51)

1. Adékambi, T., Reynaud-Gaubert, M., Greub, G., Gevaudan, M.-J., La Scola, B., Raoult, D., and Drancourt, M. (2004) Amoebal coculture of “Mycobacterium massiliense” sp. nov. from the sputum of a patient with hemoptoic pneumonia. J Clin Microbiol 42: 5493–5501.
2. Ballell, L., Bates, R.H., Young, R.J., Alvarez-Gomez, D., Alvarez-Ruiz, E., Barroso, V., et al. (2013) Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis. ChemMedChem 8: 313–321.
3. Bastian, S., Veziris, N., Roux, A.-L., Brossier, F., Gaillard, J.-L., Jarlier, V., and Cambau, E. (2011) Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 55: 775–781.
4. Belisle, J.T., Vissa, V.D., Sievert, T., Takayama, K., Brennan, P.J., and Besra, G.S. (1997) Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276: 1420–1422.
5. Bernut, A., Herrmann, J.-L., Kissa, K., Dubremetz, J.-F., Gaillard, J.-L., Lutfalla, G., and Kremer, L. (2014a) Mycobacterium abscessus cording prevents phagocytosis and promotes abscess formation. Proc Natl Acad Sci USA 111: E943–952.
6. Bernut, A., Le Moigne, V., Lesne, T., Lutfalla, G., Herrmann, J.-L., and Kremer, L. (2014b) In vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system. Antimicrob Agents Chemother 58: 4054–4063.
7. Bernut, A., Dupont, C., Sahuquet, A., Herrmann, J.-L., Lutfalla, G., and Kremer, L. (2015) Deciphering and imaging pathogenesis and cording of Mycobacterium abscessus in zebrafish embryos. J Vis Exp 103: e53130.
8. Bernut, A., Viljoen, A., Dupont, C., Sapriel, G., Blaise, M., Bouchier, C., et al. (2016) Insights into the smooth-to-rough transitioning in Mycobacterium bolletii unravels a functional Tyr residue conserved in all mycobacterial MmpL family members. Mol Microbiol 99: 866–883.
9. Bolla, J.R., Su, C.-C., Do, S.V., Radhakrishnan, A., Kumar, N., Long, F., et al. (2014) Crystal structure of the Neisseria gonorrhoeae MtrD inner membrane multidrug efflux pump. PLoS One 9: e97903.
10. Boritsch, E.C., Frigui, W., Cascioferro, A., Malaga, W., Etienne, G., Laval, F., et al. (2016) pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence. Nat Microbiol 1: 15019.
11. Brown-Elliott, B.A., and Wallace, R.J. (2002) Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 15: 716–746.
12. Byrd, T.F., and Lyons, C.R. (1999) Preliminary characterization of a Mycobacterium abscessus mutant in human and murine models of infection. Infect Immun 67: 4700–4707.
13. Catherinot, E., Roux, A.-L., Macheras, E., Hubert, D., Matmar, M., Dannhoffer, L., et al. (2009) Acute respiratory failure involving an R variant of Mycobacterium abscessus. J Clin Microbiol 47: 271–274.
14. Chim, N., Torres, R., Liu, Y., Capri, J., Batot, G., Whitelegge, J.P., and Goulding, C.W. (2015) The Structure and Interactions of Periplasmic Domains of Crucial MmpL Membrane Proteins from Mycobacterium tuberculosis. Chem Biol 22: 1098–1107.
15. Choo, S.W., Wee, W.Y., Ngeow, Y.F., Mitchell, W., Tan, J.L., Wong, G.J., et al. (2014) Genomic reconnaissance of clinical isolates of emerging human pathogen Mycobacterium abscessus reveals high evolutionary potential. Sci Rep 4: 4061.
16. Cox, J.A.G., Abrahams, K.A., Alemparte, C., Ghidelli-Disse, S., Rullas, J., Angulo-Barturen, I., et al. (2016) THPP target assignment reveals EchA6 as an essential fatty acid shuttle in mycobacteria. Nat Microbiol 1: 15006.
17. Coxon, G.D., Craig, D., Corrales, R.M., Vialla, E., Gannoun-Zaki, L., and Kremer, L. (2013) Synthesis, antitubercular activity and mechanism of resistance of highly effective thiacetazone analogues. PLoS One 8: e53162.
18. Domenech, P., Reed, M.B., and Barry, C.E. (2005) Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect Immun 73: 3492–3501.
19. Feng, X., Zhu, W., Schurig-Briccio, L.A., Lindert, S., Shoen, C., Hitchings, R., et al. (2015) Antiinfectives targeting enzymes and the proton motive force. Proc Natl Acad Sci USA 112: E7073–7082.
20. Floto, R.A., Olivier, K.N., Saiman, L., Daley, C.L., Herrmann, J.-L., Nick, J.A., et al. (2016) US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. Thorax 71: 88–90.
21. Griffith, D.E., Girard, W.M., and Wallace, R.J. (1993) Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 147: 1271–1278.
22. Grzegorzewicz, A.E., Pham, H., Gundi, V.A.K.B., Scherman, M.S., North, E.J., Hess, T., et al. (2012) Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol 8: 334–341.
23. Harada, T., Akiyama, Y., Kurashima, A., Nagai, H., Tsuyuguchi, K., Fujii, T., et al. (2012) Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol 50: 3556–3561.
24. Henkle, E., Hedberg, K., Schafer, S., Novosad, S., and Winthrop, K.L. (2015) Population-based incidence of pulmonary nontuberculous mycobacterial disease in Oregon 2007 to 2012. Ann Am Thorac Soc 12: 642–647.
25. Howard, S.T., Rhoades, E., Recht, J., Pang, X., Alsup, A., Kolter, R., et al. (2006) Spontaneous reversion of Mycobacterium abscessus from a smooth to a rough morphotype is associated with reduced expression of glycopeptidolipid and reacquisition of an invasive phenotype. Microbiology 152: 1581–1590.
26. Hutchinson, A.J., Chenard, B.L., Li, G., Gosh, M., Tarrant, J.G., Yoon, T., et al. (2006) Preparation of aryl-substituted piperazine derivatives as MCH modulators. Assignee: Neurogen Corporation, USA Jan 12, 2006 US 20060009456 A1.
27. Kelley, L.A., Mezulis, S., Yates, C.M., Wass, M.N., and Sternberg, M.J.E. (2015) The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc 10: 845–858.
28. Koh, W.-J., Jeon, K., Lee, N.Y., Kim, B.-J., Kook, Y.-H., Lee, S.-H., et al. (2011) Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 183: 405–410.
29. Kremer, L., Guérardel, Y., Gurcha, S.S., Locht, C., and Besra, G.S. (2002) Temperature-induced changes in the cell-wall components of Mycobacterium thermoresistibile. Microbiology 148: 3145–3154.
30. La Rosa, V., Poce, G., Canseco, J.O., Buroni, S., Pasca, M.R., Biava, M., et al. (2012) MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother 56: 324–331.
31. Lamason, R.L., Mohideen, M.-A.P.K., Mest, J.R., Wong, A.C., Norton, H.L., Aros, M.C., et al. (2005) SLC24A5, a putative cation exchanger, affects pigmentation in zebrafish and humans. Science 310: 1782–1786.
32. Lobo, L.J., Chang, L.C., Esther, C.R., Gilligan, P.H., Tulu, Z., and Noone, P.G. (2013) Lung transplant outcomes in cystic fibrosis patients with pre-operative Mycobacterium abscessus respiratory infections. Clin Transplant 27: 523–529.
33. Lun, S., Guo, H., Onajole, O.K., Pieroni, M., Gunosewoyo, H., Chen, G., et al. (2013) Indoleamides are active against drug-resistant Mycobacterium tuberculosis. Nat Commun 4: 2907.
34. Marras, T.K., Chedore, P., Ying, A.M., and Jamieson, F. (2007) Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003. Thorax 62: 661–666.
35. Maurer, F.P., Bruderer, V.L., Ritter, C., Castelberg, C., Bloemberg, G.V., and Böttger, E.C. (2014) Lack of antimicrobial bactericidal activity in Mycobacterium abscessus. Antimicrob Agents Chemother 58: 3828–3836.
36. Mirsaeidi, M., Farshidpour, M., Allen, M.B., Ebrahimi, G., and Falkinham, J.O. (2014) Highlight on advances in nontuberculous mycobacterial disease in North America. Biomed Res Int 2014: 919474.
37. Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., Goodsell, D.S., and Olson, A.J. (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30: 2785–2791.
38. Murakami, S. (2008) Multidrug efflux transporter, AcrB–the pumping mechanism. Curr Opin Struct Biol 18: 459–465.
39. Nessar, R., Cambau, E., Reyrat, J.M., Murray, A., and Gicquel, B. (2012) Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 67: 810–818.
40. Palomino, J.-C., Martin, A., Camacho, M., Guerra, H., Swings, J., and Portaels, F. (2002) Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 46: 2720–2722.
41. Payne, D.J., Gwynn, M.N., Holmes, D.J., and Pompliano, D.L. (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29–40.
42. Philley, J.V., Wallace, R.J., Benwill, J.L., Taskar, V., Brown-Elliott, B.A., Thakkar, F., et al. (2015) Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease. Chest 148: 499–506.
43. Remuiñán, M.J., Pérez-Herrán, E., Rullás, J., Alemparte, C., Martínez-Hoyos, M., Dow, D.J., et al. (2013) Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6′,7′-dihydrospiro[piperidine-4,4′-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3. PLoS One 8: e60933.
44. Ripoll, F., Pasek, S., Schenowitz, C., Dossat, C., Barbe, V., Rottman, M., et al. (2009) Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PLoS One 4: e5660.
45. Sandhu, P., and Akhter, Y. (2015) The internal gene duplication and interrupted coding sequences in the MmpL genes of Mycobacterium tuberculosis: towards understanding the multidrug transport in an evolutionary perspective. Int J Med Microbiol 305: 413–423.
46. Singh, S., Bouzinbi, N., Chaturvedi, V., Godreuil, S., and Kremer, L. (2014) In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex. Clin Microbiol Infect 20: O1124–1127.
47. Stover, C.K., De la Cruz, V.F., Fuerst, T.R., Burlein, J.E., Benson, L.A., Bennett, L.T., et al. (1991) New use of BCG for recombinant vaccines. Nature 351: 456–460.
48. Tahlan, K., Wilson, R., Kastrinsky, D.B., Arora, K., Nair, V., Fischer, E., et al. (2012) SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 1797–1809.
49. Trott, O., and Olson, A.J. (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31: 455–461.
50. Varela, C., Rittmann, D., Singh, A., Krumbach, K., Bhatt, K., Eggeling, L., et al. (2012) MmpL genes are associated with mycolic acid metabolism in mycobacteria and corynebacteria. Chem Biol 19: 498–506.
51. Woods, G.L., Brown-Elliott, B.A., Conville, P.S., Desmond, E.P., Hall, G.S., Lin, G., et al. (2011) Susceptibility Testing of Mycobacteria, Nocardiae and Other Aerobic Actinomycetes: Approved Standard. Second Edition. M24-A2. Wayne, PA: Clinical and Laboratory Standards Institute, 2011.